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Abstract
Background:In preparation for a cluster-randomized controlled trial of a community intervention
to increase the demand for measles vaccination in Lasbela district of Pakistan, a balance sheet
summarized published evidence on benefits and possible adverse effects of measles vaccination.
Methods:The balance sheet listed:1) major health conditions associated with measles;2) the risk
among the unvaccinated who contract measles; 3) the risk among the vaccinated; 4) the risk
difference between vaccinated and unvaccinated;and 5) the likely net gain from vaccination for each
condition.
Results: Two models revealed very different projections of net gain from measles vaccine.
A Lasbela-specific combination of low period prevalence of measles among the unvaccinated,
medium vaccination coverage and low vaccine efficacy rate, as revealed by the baseline survey,
resulted in less-than-expected gains attributable to vaccination. Modelled on estimates where the
vaccine had greater efficacy, the gains from vaccination would be more substantial.
Conclusions: Specific local conditions probably explain the low rates among the unvaccinated
while the high vaccine failure rate is likely due to weaknesses in the vaccination delivery system.
Community perception of these realities may have had some role in household decisions about
whether to vaccinate, although the major discouraging factor was inadequate access.The balance
sheet may be useful as a communication tool in other circumstances, applied to up-to-date local
evidence.
Open AccessBackground 
In early 2005, preparations began for a cluster-random-
ized controlled trial of a knowledge translation (KT)
intervention to increase the demand for measles vaccina-
tion in Lasbela district of Balochistan province, Pakistan.
Separate articles discuss the protocol [1], baseline find-
ings [2], and the outcome of the trial [3].
The team worked from a defined theoretical position. We
assumed that household decisions are fundamentally
rational, at least in the sense that families weigh up costs
and benefits of having their children vaccinated [4-6]. 
Early in the planning stages for the trial, well before con-
ducting and analyzing the baseline survey, we expected to
encounter concern over the potential adverse effects of
measles vaccine. Previous work on child vaccination in
the region had encountered a number of negative views.
There was also a small but important international litera-
ture on the subject. Three majority-Muslim States in
Nigeria at one time or another stopped internationally
sanctioned polio vaccination campaigns based on con-
spiracy theories that the vaccination was a Western plot to
sterilize children and even spread HIV among them [7].
In Europe and North America concerns about possible
connections between the MMR vaccine and autism had
been circulating in the media for years [8]. 
If these or similar concerns were raised at community
level in Lasbela, we anticipated they would have to be
addressed with full and accurate information. We pre-
pared for this KT by designing a tool for discussing with
the communities specific gains and losses to be anticipat-
ed from measles vaccination – the Lasbela Vaccination
Balance Sheet.
The balance sheet went through a series of steps that are
diagrammed in the left-hand column of Figure 1. Our first
step was to gather the necessary data from developed-
country sources from which almost all available estimates
of measles complication rates and vaccination adverse
effects are derived. After drawing up the balance sheet
based on these estimates we then added parallel estimates
for the major adverse effects under local conditions using
whatever data were available on Lasbela, Balochistan,
Pakistan or South Asia prior to our own baseline survey.
The results of these steps are combined in Table 1.
Outcomes of the baseline survey obliged us to modify our
assumptions and recalculate the balance sheet. The main
differences between our estimates prior to and after the
baseline survey are presented in Table 2.
Methods
A balance sheet synthesized published information on
risks of adverse effects of vaccination and risks for the
same outcomes as complications of naturally occurring
measles. We presented the difference in risk of each out-
come between vaccinated and unvaccinated children as
the risk difference (RD). Where the literature provided a
range for the unvaccinated, we used the lower figure in the
calculation. The inverse of the RD is the number needed
to treat (NNT), the number of persons that must be vac-
cinated in order to avoid one case of the negative
outcome, and the number needed to harm (NNH), the
number that must be vaccinated to produce one case
of harm.
We presented the data in terms of “gains,” the potential
number of cases of the outcome (or complication) pre-
vented if all children currently unvaccinated were
vaccinated for measles. The gain is calculated by multi-
plying the RD by the proportion requiring the
intervention (PRI) and adjusting for vaccine efficacy [9].
The first model of expected gains used our original
assumptions about conditions in Lasbela, before analysis
of the 2005 baseline survey. We applied a PRI of 0.76
based on the overall vaccination rate reported for
Balochistan province in 2001-02 according to the
Pakistan Integrated Household Survey, Round 4 [10]. We
assumed a vaccine efficacy rate (VER) of 90%, which is at
the low end of estimates provided in the literature for
developed countries [11]. 
For adverse effects, we consulted a 2005 comprehensive
review of measles, mumps and rubella (MMR) vaccine
effects published by the Cochrane Collaboration [12]. Of
31 studies that met the Cochrane review’s inclusion crite-
ria, we selected those 20 that contained specific numbers
of adverse effect cases together with the total study popu-
lation [13-32]. We extracted these data to create tables for
each adverse effect (AE table) in a spreadsheet workbook. 
We linked the rate of occurrence for each adverse effect in
the table to the appropriate cell in the summary balance
sheet. Due to time and resource constraints we did not
assign credibility weights to each study. A summary rate of
occurrence is derived from the total of adverse event cases
divided by the total of the study populations reported by
our sources for each adverse effect. Where there were no
population-based AE data to match with a known com-
plication of naturally occurring measles we use rates
estimated by Duclos and Ward [33].
To obtain complication rates among the unvaccinated
with measles, we consulted World Health Organization
(WHO) documents [34-36], a standard textbook on the
subject [37] and the sources these cited. Most sources for
complication rates among the unvaccinated provide fig-
ures based on conditions in the developed world,
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certain conditions in the developing world. In order to
develop figures approximating conditions in Pakistan, we
adjusted the complication rates for pneumonia and diar-
rhoea using regional incidence rates for these diseases
(from all causes) based on data reported by WHO [38].
Pakistan is part of WHO’s Eastern Mediterranean Region
(EMRO), mortality substratum D. We calculated the rates
of incidence of pneumonia (lower respiratory infections)
and diarrhoea for EMRO-D and used European region
substratum A as a comparison. 
The adjustment for pneumonia applies the proportional
difference in incidence rates for lower respiratory infections
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Figure 1 - Model of measles balance sheet development.
Lasbela pilot experience  Proposed future developments
Repetition of above process 
for other vaccines
Internet posting of 
country measles
balance sheets
Preparation of country 
measles balance sheets
Country & local surveys
Preparation of measles 
balance sheets based 
on data from other 
WHO regions and 
subregions
Internet posting of measles 
balance sheets for each 
WHO region or subregion 
for improve-ments and 
updating 
Internet posting of 
developed countries' 
measles balance sheet 
for improvement and 
updating 
Adaptation of balance 
sheet to Lasbela 
conditions in light of 
baseline survey
Local baseline survey 
Adaptation of measles 
balance sheet to 
approximate local 
conditions based on
data available prior to 
baseline survey
Preparation of initial 
measles balance sheet 
on basis of data from 
developed countries
Literature reviews on
adverse effects of 
measles vaccination and 
complication rates among 
unvaccinated (from all causes) for the Euro-A and EMRO-D substrata
(EMRO-D (42,687/351,256=0.12) Euro-A (5,649/
412,512=0.01). The EMRO-D rate is 12 times the Euro-A
rate (0.12/0.01). We used the same procedure for diarrhoea
(EMRO-D (345,605/351,256=0.98) Euro-A (79,219/
412,512=0.19). The EMRO-D incidence rate is 5.2 times
that of Euro-A (0.98/0.19). The balance sheet reports fig-
ures for the base rate (developing world conditions) and
EMRO-D adjusted rates (Pakistan conditions) for diar-
rhoea and pneumonia.
For a closer estimate of deaths due to naturally occurring
measles in Pakistan, we divided the number of measles
deaths for the year 2002 in WHO’s EMRO-D region
(70,392) [39] by measles incidence in that region
(3,079,000) in the same year [40]. The rate thus derived
is almost certainly underestimated. To provide an outer
limit closer to reality in Pakistan, we also included gains
calculations based on a death rate of 15%, which was
suggested in other sources consulted as appropriate for
developing countries [41]. It was assumed that virtually
all the unvaccinated were likely to contract measles. In
this we followed White and colleagues who reported
that, according to United States records from the period
previous to the introduction of measles vaccine, 95% of
individuals in an unvaccinated population had evidence
of measles infection by age 30 [42]. The vast majority of
these infections are likely to have occurred in early
childhood.
Blindness is usually reported as a complication of measles
in the developing world, though not in the developed
world. No base complication rates for the developing
world were provided in any of the sources consulted. It
BMC International Health and Human Rights 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1472-698X/9/S1/S6
Page 4 of 9
(page number not for citation purposes)
Table 1 - Original Measles Vaccination Balance Sheet.
(2) Measles complication  (3) Vaccine adverse (5) Number Needed (6) Expected Gain
(1) Condition rate among unvaccinateda event rate  (4) Risk Difference to Treat (NNT) per thousande
Diarrhoea in highly  0.08 0.0357 0.0443 23 30
developed countries
Diarrhoea – WHO South Asia  0.41 0.0045 0.4055 3 277
subregion adjusted 
Bronchopneumonia in highly  0.01-0.06 0 0.01 100 7
developed countries
Bronchopneumonia – WHO   0.089-0.53 0 0.089 11 61
South Asia subregion adjusted
Blindness (Africa) 0.04b 0 0.04 25 27
Otitis media 0.07–0.09 0.0333 0.0367 27 25
Death in highly developed countries 0.001–0.003 0.0002 0.0008 1,189 0.6
Death – WHO South Asia subregion data 0.0228 0.0002 0.0208 50 14
Death in developing world 15% 0.0002 0.1498 7 102
(by some estimates)
Convulsions 0.006–0.007c 0.0022 0.0038 266 3
Post-infectious encephalitis 0.001–0.0005 0.0004 0.0006 1,591 0.4
Subacute sclerosing panencephalitis (SSPE) 0.00001 0 0.00001 100,000 7/million
Anaphylaxis 0d 1–3.5 per million –0.000001 –1,000,000 –7/ten million
a Except where noted all figures in this column taken from Strebel et al [44]. b [45]. c [51]. d [33].
e Gain=RDx(PRIxVER), where RD=risk difference, PRI=proportion requiring intervention (0.76),VER=vaccine efficacy rate (0.90).
The bold-font rows show the conditions for which the data are most applicable to the South Asia region or, at least, developing country conditions -
diarrhoea, pneumonia, blindness and death.
Table 2 - Anticipated population gains and losses – cases of the
condition prevented or caused if all children currently unvaccinated were
vaccinateda.
Expected gain (number 
Expected gain (number prevented) applying
prevented) under  efficacy rates from 
Condition original assumptions Lasbela baseline surveyb
Diarrhoea 277 per thousand 30 per thousand
Bronchopneumonia 61 per thousand 7 per thousand
Blindness 27 per thousand 3 per thousand
Otitis media 25 per thousand 3 per thousand
Death 14 per thousand 15 per ten thousand
Convulsions 3 per thousand 3 per ten thousand
Post-infectious  4 per ten thousand 5 per hundred thousand
encephalitis 7 per million 7 per ten million
SSPE Losses (original  Losses after 
assumptions) baseline survey
Anaphylaxis 7 per ten million 7 per hundred million
a Sources for all calculations are the same as in Table 1. Differences in
gains are due to revised assumptions following the baseline survey.
b Gain=[RDx(PRIxVER)] x 0.361, where RD=Risk difference,
PRI=proportion requiring intervention (0.49), and VER=Vaccine efficacy
rate (0.415).
The bold-font rows show the conditions for which the data are most
applicable to the South Asia region or, at least, developing country
conditions - diarrhoea, pneumonia, blindness and death.appears that little of the research on blindness in the
developing world is population-based [43]. We found a
single source that provided population-based rate of
blindness as a complication for measles in Africa [44].
Despite the geographical and social difference with
Pakistan we included it in the balance sheet as our only
point of comparison. 
Adverse effects among the vaccinated
Some adverse effects of measles vaccination did not
appear in any of the sources as complications among the
unvaccinated with measles. Most of these are local and/or
mild reactions (e.g. fever, rash, redness, swelling, etc.), but
some, such as anaphylaxis, though rare, do appear to occur
among the vaccinated more than among naturally occur-
ring measles cases. Another rare adverse effect is idiopathic
thrombocytopenic purpura (ITP). We did not include it in
the balance sheet because it seems to be associated with
MMR vaccine rather than monovalent measles vaccines
used in Pakistan [33]. Other reported adverse effects, lack-
ing evidence of causal association, include Reye’s
syndrome, oculomotor palsy, optic neuritis, retinopathy,
hearing loss, cerebellar ataxia, arthralgia, arthritis, soft tis-
sue reactions, and Guillain-Barre syndrome. The sources
consulted also reported certain “described” complica-
tions, but without rates of occurrence. These include
thrombocytopenia, laryngotracheo-bronchitis, stomatitis,
hepatitis, appendicitis and ileocolitis, pericarditis and
myocarditis, glomerulonephritis, hyopcalcemia and
Stevens-Johnson syndrome [44,45].
The articles from the Cochrane review, our point of depar-
ture, did not report rates of death among the vaccinated
(i.e. as an adverse effect). We used two cost-benefit articles
that provided estimates for this group derived from their
models [42,46].
Results 
The original balance sheet
The summary balance sheet presented in Table 1 repro-
duces the summary worksheet of the spreadsheet
workbook. [The workbook itself is available from the
authors.] The bold-font rows of Tables 1 and 2 show the
conditions for which the data are most applicable to the
South Asia region or, at least, developing country condi-
tions – diarrhoea, pneumonia, blindness and death.
The risk difference and its inverse (NNT) indicate the
broad level of public health importance of measles vacci-
nation, taking into account the adverse effects. In the case
of anaphylaxis, there is a balance unfavourable to vacci-
nation of about one in a million. Otherwise the balance
favouring vaccination is clear: 277 cases of diarrhoea, 61
of pneumonia, 27 of blindness and 14 deaths prevented
for every thousand children vaccinated.
After the baseline survey
Table 1 was based on a set of assumptions that did not
prove to be valid in the case of Lasbela as revealed in the
baseline survey [47].
Our concern at the design stage that fear of potential
adverse effects of vaccination would be an obstacle to vac-
cination coverage proved to be unfounded. In the
baseline survey, household decision makers were asked
whether they had heard about bad effects of vaccination,
whether they had seen bad effects of vaccination and
whether they knew some of the dangerous or severe com-
plications of measles. The answers to these questions,
whether positive or negative, had no significant effect on
the decision to have the child vaccinated or not.
Only 4% (118/3251) of decision makers had heard of any
adverse effect of vaccination. Most of the adverse effects
they mentioned were recognised ones, including fever
and swelling or pain at the injection site. A few (less than
1%) mentioned things that are not recognised adverse
effects of vaccination and among these only a handful
mentioned “family planning” signifying the belief that
vaccinations will make children sterile or cause them to
have only female children in the future. Some 58%
(1913/3299) of decision makers reported they knew
about some dangerous or severe complications if measles
were to get worse. Participants in many focus groups
made it clear they knew how serious an illness like
measles could be and they mentioned some of the poten-
tial consequences of measles, including death.
The baseline survey results also called into question three
assumptions on which the data of our original balance
sheet were based: 
1. Unvaccinated children do not all get measles. The base-
line survey found that only 36% of unvaccinated children
under five years of age had contracted measles before their
fifth birthday. Children from urban households – only
about a quarter of the total sample – were more likely to
have had measles than rural children (weighted OR
1.64 95%CI 1.36-1.97). When asked how common
they thought measles was in their area most decision
makers (91%; 3010/3314) said they thought it was rare.
2. Measles vaccination coverage in Lasbela was higher
than the rate for Balochistan that we used in the origi-
nal balance sheet. The PRI, estimated at 76% in our
original balance sheet was only 49% according to the
baseline survey.
3. The baseline survey revealed that the VER was 41.5%, less
than half that assumed in the original balance sheet. The
VER calculation is based on all children from 10 to 60
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those who had measles before the age of 10 months, and
children who were vaccinated only after having measles
or within one month before having measles. The measles
attack rate among vaccinated children (ARv) in this
group was 12.8% (255/1988) while the attack rate
among the unvaccinated (Aru) was 21.9% (386/1759)
[47].  We then derived the VER from the formula:
VER = 1 – (Arv/ARu) [48].
Given these three realities, our original balance sheet con-
siderably overstated the protection that vaccination
would provide against the various conditions listed there,
as can be seen from Table 2. 
The proportions presented in the third column of Table 2
are based on the same risk differences as in Table 1, but the
PRI is 0.49 instead of 0.76 and the VER is 0.415 instead of
0.90. Also, instead of assuming that virtually all unvacci-
nated children would contract the disease, we further
adjusted the resulting gains to the proportion of unvacci-
nated children less than five years of age who ever had
measles in Lasbela according to the baseline survey (0.361). 
The real concerns of the communities
Lasbela parents, by and large, were convinced their chil-
dren should be vaccinated. The baseline showed that 90%
of those who make the decisions about vaccination with-
in Lasbela families thought it was worthwhile, 8% did not
know whether it was worthwhile or not and only 2%
thought it was not worthwhile.
When decision makers were asked about the difficulties
households may face in getting their children immunized,
more than half reported that access was a problem either
because there were no nearby facilities offering vaccina-
tion or vaccination teams did not visit (35%), or because
of transport problems or poor roads (24%). When asked
what would ensure that every child in the household was
immunized nearly all responses were related to improv-
ing access (92%). 
In the end, the balance sheet was not used as part of the
Lasbela intervention. Instead, community discussions
focused on the relative costs of treating measles cases ver-
sus the costs of preventing measles through
immunization, as well as on the barriers to obtaining
immunization services [3]. 
Discussion 
Usefulness of the balance sheet
The balance sheet was not used as part of the intervention
because possible adverse effects of vaccination were not a
community concern. The major obstacle to improved vac-
cination rates in Lasbela proved to be the lack of access. 
We had anticipated greater concern over the potential
adverse effects of measles vaccine than we encountered
among Lasbela families. Both the baseline survey and
discussions held with non-sample communities during
the design phase of the intervention indicated clearly that
belief in the efficacy of the vaccine was not a significant
factor in household decisions; the overwhelming concern
was about the costs of having children vaccinated. These
were costs in time, transport and money, resulting in a
tendency to postpone having one’s child vaccinated
and/or discount the likelihood that one’s own child
might fall prey to the disease [3]. 
Our theoretical position concerning the rationality of
household decisions was too broad to be applicable in
the concrete circumstances of Lasbela in 2005-2007. The
household decision-making revealed in this experience
corresponded more to Herbert Simon’s concept of
“bounded rationality” [49]. In the words of a contempo-
rary heir to Simon’s insights, “...the human mind makes
many decisions by drawing on an adaptive toolbox of
simple heuristics, not because it is forced to by cognitive
constraints, but rather because these fast and informa-
tion-frugal heuristics are well matched to the challenges
of the ... environment”[50]. The environmental chal-
lenges most operative in the Lasbela situation were
distance and poverty. Knowledge about vaccination was
high, attitudes toward it were positive and there was a
good deal of discussion within the household about vac-
cination, but there was little concern about possible
adverse effects [2].
Still, people have a right to know about possible adverse
effects of any vaccination. We believe that the relevant
information should be available to those who request it
and in a form that enables them to weigh costs and ben-
efits – in terms of adverse effects and complications – of
both being vaccinated and not being vaccinated. In other
places and under other conditions the potential adverse
effects of measles vaccine could be an important deterrent
to vaccination. The balance sheet can provide the neces-
sary information in a concise and useful form that will
enable people and communities to make rational choices
in this regard. 
Vaccine failure
The objective of the Lasbela trial was to demonstrate
that informed discussion of costs and benefits could
improve demand for vaccination, without relying on
improvements in health service delivery. An unvaccinat-
ed child still had twice the risk of contracting measles
compared to one who was vaccinated. The Lasbela pop-
ulation evidently perceived this as a positive effect, but
the odds in favour of vaccination could and should have
been much higher. 
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in vaccine delivery is necessary. The failure rate of over
50% means a partial breakdown in the cold chain or,
more likely, its inappropriate management at the point of
delivery (for example, partially used multi-shot vials left
open or in the light). 
Measles among the unvaccinated
The relatively low rate of measles among the unvaccinat-
ed can be explained by the scattered and relatively
isolated nature of communities in many rural areas of
Lasbela. This apparently creates an environment less con-
ducive to the spread of naturally occurring measles. This
conjecture is reinforced by the somewhat higher rates
among the minority of children in the denser urban areas
[2]. Nine out of ten respondents thought that measles was
a relatively rare occurrence in Lasbela and this, too, is like-
ly to have influenced the household cost-benefit
calculations about vaccination.
Limitations of the balance sheet
We were unable to find published data about complica-
tions among the unvaccinated or adverse effects of measles
vaccination from Pakistan or anywhere in the South Asia
sub-region. The extrapolations to South Asia for diarrhoea
and pneumonia rates among the unvaccinated are crude
estimates at best, based on ratios of diarrhoea and pneu-
monia occurrence for any cause between one large WHO
region and another. Complication rates among the unvac-
cinated for otitis media, anaphylaxis, convulsions,
encephalitis and SSPE reported are based only on devel-
oped country conditions, which are quite different. 
The balance sheet does not allow for differences in the
severity and duration of the conditions it lists. Measles vac-
cination is known to have a limiting effect in many cases on
the severity and duration of common illnesses such as diar-
rhoea and respiratory disease, but such effects are not taken
into account by this instrument. The rates recorded in
columns 2 and 3 of Table 1 are for people of any age where-
as our gains calculations apply only to children under five
years of age. As the practice of generating balance sheets
grows, these deficiencies could be improved upon.
We did not determine whether the adverse effects report-
ed by our developed-country sources were reported before
or after the introduction of a two-dose regimen for
measles vaccine. The likelihood of at least some adverse
effects should be higher in the developed countries where
two doses is the norm than in developing countries like
Pakistan where it is not. 
We made no adjustments for vaccine strain. The studies
we used for adverse effects came from a review of MMR
vaccine. Adverse effects of single measles vaccine cannot
always be easily isolated from those of the triple vaccine
as reported in our sources. We did not weight the data
from the different studies on adverse effects according to
their risk of bias. 
Conclusions 
The balance sheet may be useful as a communication tool
in many other circumstances, but it needs to be tested
against up-to-date local evidence in other countries.
If the necessary resources become available, CIET hopes to
develop and expand the balance sheet into a web-based
tool accessible for critical peer review and eventual public
use. We will first have to find ways to overcome as many
of the limitations mentioned above as possible. Such a
tool could be regularly updated with new research and
become a timesaving reference for project managers and
heath officials concerned with vaccination. 
Figure 1 outlines a possible set of steps toward this end.
Since most of the available data on vaccine adverse effects
come from developed country sources, the logical starting
point would be to post a developed-countries balance
sheet and refine it based on critical comments and addi-
tional information. The long-term goal, however, should
be to have a set of balance sheets for each developing
country based on population surveys of measles occur-
rence. As an intermediary step balance sheets can be
developed for WHO regions and sub-regions using data
similar to those we used from the WHO South Asia sub-
region in which Pakistan is located. Country surveys that
include information about vaccine adverse effects will
help gradually to improve the quality of these regional
and sub-regional balance sheets as well.
Country surveys are also helpful for testing vaccine effica-
cy which, as we have seen, is crucial not only for the
balance sheet but for the credibility of the entire vaccina-
tion enterprise.
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